Literature DB >> 18467710

Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression.

Tait D Shanafelt, Curtis Hanson, Gordon W Dewald, Thomas E Witzig, Betsy LaPlant, Jennifer Abrahamzon, Diane F Jelinek, Neil E Kay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18467710      PMCID： PMC3913538          DOI： 10.1200/JCO.2008.16.7874

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

2.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Thomas E Witzig; Stephanie R Fink; Robert B Jenkins; Sarah F Paternoster; Stephanie A Smoley; Kimberly J Stockero; Danielle M Nast; Heather C Flynn; Renee C Tschumper; Susan Geyer; Clive S Zent; Tim G Call; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

3.  Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.

Authors:  Valter Gattei; Pietro Bulian; Maria Ilaria Del Principe; Antonella Zucchetto; Luca Maurillo; Francesco Buccisano; Riccardo Bomben; Michele Dal-Bo; Fabrizio Luciano; Francesca M Rossi; Massimo Degan; Sergio Amadori; Giovanni Del Poeta
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

4.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

5.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
  5 in total
  21 in total

1.  Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Matthew T Drake; Matthew J Maurer; Cristine Allmer; Kari G Rabe; Susan L Slager; George J Weiner; Timothy G Call; Brian K Link; Clive S Zent; Neil E Kay; Curtis A Hanson; Thomas E Witzig; James R Cerhan
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

2.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Roxane Collins; Sajid Shakhan; Jinghui Li; Edward Peres; Lisa Kujawski; Moshe Talpaz; Mark Kaminski; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

Review 3.  Evolving understanding of the CLL genome.

Authors:  Michaela Gruber; Catherine J Wu
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

4.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

5.  Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Kamlai Saiya-Cork; Erlene Seymour; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

6.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

7.  A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.

Authors:  Nisar A Amin; Erlene Seymour; Kamlai Saiya-Cork; Brian Parkin; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

Review 8.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

9.  CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.

Authors:  Boris A Bartholdy; Xiahoua Wang; Xiao-Jie Yan; Marién Pascual; Manxia Fan; Jacqueline Barrientos; Steven L Allen; Jose Angel Martinez-Climent; Kanti R Rai; Nicholas Chiorazzi; Matthew D Scharff; Sergio Roa
Journal:  Blood Adv       Date:  2020-03-10

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.